logo
Plus   Neg
Share
Email

Paladin Labs Reports Approval Of Envarsus PA In Canada

Paladin Labs Inc. and Endo Ventures Limited, subsidiaries of Endo International plc (ENDP), announced Health Canada's approval of Envarsus PA (tacrolimus prolonged-release tablets) for the prophylaxis of organ rejection in kidney or liver transplant adult patients (in combination with other immunosuppressants). Envarsus PA is marketed in Canada by Paladin Labs Inc.

"We believe the launch of Envarsus PA will provide kidney or liver transplant patients with an important alternative in immunosuppression, enhancing therapeutic options for those patients and for healthcare providers. We are committed to supporting continued innovation in transplantation to help Canadian patients with unmet needs," said Livio Di Francesco, Vice President & General Manager of Paladin Labs Inc.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
AT&T Inc. (T) reported first-quarter adjusted earnings per share of $0.86 compared to $0.85, prior year. On average, 23 analysts polled by Thomson Reuters expected the company to report profit per share of $0.86 for the quarter. Analysts' estimates typically exclude special items. Adjusting for amortization,... Shares of Credit Suisse Group AG were gaining around 3 percent in Swiss trading after the banking major reported Wednesday higher profit in its first quarter, despite weak revenues. Looking ahead, the company said it is cautiously optimistic about its prospects for the second quarter of 2019. The company remains focused on increasing its returns over the course of 2019 and beyond. While reporting financial results for the first quarter, Thermo Fisher Scientific Inc. (TMO) on Wednesday raised its adjusted earnings and revenue guidance for the full year 2019 to reflect strong operational performance and the acquisition of Brammer Bio, partially offset by a more adverse foreign exchange...
Follow RTT